The AMAC Action Government Relations Team was recently contacted by the office of Senator Marsha Blackburn (R-TN) to review her and co-sponsor Senator Bob Menendez’s (D-NJ) bill to address the foreign manufacturing, specifically Chinese, of active ingredients for pharmaceutical products used in the United States. Among other initiatives, the bill would bring this manufacturing back to the United States by expanding the Food and Drug Administration’s Emerging Technologies Program to speed technologies that would address drug shortages and create a skilled pharmaceutical manufacturing workforce in America. AMAC members have voiced their support for breaking American dependence on Chinese pharmaceuticals and AMAC Action is proud to support this bill on their behalf.
April 21, 2020
The Honorable Marsha Blackburn The Honorable Bob Menendez
357 Dirksen Senate Office Building 528 Hart Senate Office Building
Washington, DC 20510 Washington, DC 20510
Dear Senators Blackburn and Menendez,
On behalf of our more than 2.1 million members, the Association of Mature American Citizens (AMAC) is writing in support of the Securing America’s Medicine Cabinet (SAM-C) Act of 2020, S. 3432. This bipartisan legislation would reduce American reliance on foreign manufacturing of active pharmaceutical ingredients (APIs). An increase in American-based pharmaceutical production would make for a healthier America.
APIs are an essential component for finished prescription drugs, many of which are prescribed for mature Americans to help promote both good health and quality of life. However, only 28 percent of API producing facilities are located in America. The U.S. has become increasingly dependent upon China, a country lacking effective manufacturing safety regulations and oversight, for prescription drugs. In the past, Americans have been put at risk for contaminated drugs and drug shortages. As a result of the coronavirus pandemic, it has become abundantly clear America must rely on its own resources to stay safe and healthy.
This legislation would expand the U.S. Food and Drug Administration’s (FDA) Emerging Technology Program to develop technologies that can address replenishing the national strategic stockpile, eliminate critical drug shortages, and create pharmaceutical manufacturing jobs at home by ensuring that the workforce has the necessary training needed to innovate new APIs on U.S. soil. AMAC unequivocally supports addressing dangerous drug shortages as well as eliminating the threat of harmful imported medicines.
The SAM-C Act would bring drug manufacturing back to the United States, securing citizens have better access to medication they need. AMAC appreciates the bipartisan efforts by Senator Marsha Blackburn (R-TN) and Senator Bob Menendez (D-NJ) for introducing this important legislation. AMAC is proud to support S. 3432, a bill that strengthens the American pharmaceutical supply chain and prioritizes the safety of U.S. citizens.